Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder

Epigenetics

Volumn 6, Issue 12, 2011, Pages 1454-1462

  Dammann, Gerhard ^a,c   Teschler, Stefanie ^b   Haag, Tanja ^b   Altmüller, Franziska ^b   Tuczek, Frederik ^b   Dammann, Reinhard H ^b  

^a Psychiatric Hospital   (Switzerland)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Borderline personality disorder; DNA methylation; Epigenetics; Neuropsychiatric genes; Psychopathology

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT POLYPEPTIDE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEURONAL NITRIC OXIDE SYNTHASE; NR3C1 GENE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR 1B; SEROTONIN RECEPTOR 2A; SEROTONIN TRANSPORTER; SOLUBLE CATECHOL METHYLTRANSFERASE; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; BORDERLINE STATE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DAT1 GENE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA METHYLATION; FEMALE; GENE; HUMAN; MALE; NEUROPSYCHIATRY;

EID: 83255166570     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.12.18363     Document Type: Article

References (75)

1. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-98; http://dx.doi.org/10.1038/nrg2005.
2. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315-9; http://dx.doi.org/10.1038/77083.
3. van Vliet J, Oates NA, Whitelaw E. Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 2007; 64:1531-8; http://dx.doi.org/10.1007/s00018-007-6526-z.
4. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; http://dx.doi.org/10.1016/j.cell.2007.01.029.
5. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8:355-67; http://dx.doi.org/10.1038/nrn2132.
6. Abdolmaleky HM, Smith CL, Zhou JR, Thiagalingam S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol 2008; 448:187-212; http://dx.doi.org/10.1007/978-1-59745-205-2_9.
7. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209-13; http://dx.doi.org/10.1038/321209a0.
8. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006; 103:1412-7; http://dx.doi.org/10.1073/pnas.0510310103.
9. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39:457-66; http://dx.doi.org/10.1038/ng1990.
10. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet 2011; 377:74-84; http://dx.doi.org/10.1016/S0140-6736(10)61422-5.
11. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet 2004; 364:453-61; http://dx.doi.org/10.1016/S0140-6736(04)16770-6.
12. APA. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Washington DC 1994.
13. Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, correlates, disability and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69:533-45; http://dx.doi.org/10.4088/JCP.v69n0404.
14. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001; 58:590-6; http://dx.doi.org/10.1001/archpsyc.58.6.590.
15. Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. Hosp Community Psychiatry 1991; 42:1015-21.
16. Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al. Functional impairment in patients with schizotypal, borderline, avoidant or obsessive-compulsive personality disorder. Am J Psychiatry 2002; 159:276-83; http://dx.doi.org/10.1176/appi.ajp.159.2.276.
17. Kraus A, Esposito F, Seifritz E, Di Salle F, Ruf M, Valerius G, et al. Amygdala deactivation as a neural correlate of pain processing in patients with borderline personality disorder and co-occurrent posttraumatic stress disorder. Biol Psychiatry 2009; 65:819-22; http://dx.doi.org/10.1016/j.biopsych.2008.10.028.
18. APA. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001; 158:1-52.
19. Siever LJ, Torgersen S, Gunderson JG, Livesley WJ, Kendler KS. The borderline diagnosis III: identifying endophenotypes for genetic studies. Biol Psychiatry 2002; 51:964-8; http://dx.doi.org/10.1016/S0006-3223(02)01326-4.
20. Skodol AE, Siever LJ, Livesley WJ, Gunderson JG, Pfohl B, Widiger TA. The borderline diagnosis II: biology, genetics and clinical course. Biol Psychiatry 2002; 51:951-63; http://dx.doi.org/10.1016/S0006-3223(02)01325-2.
21. Torgersen S, Czajkowski N, Jacobson K, Reichborn-Kjennerud T, Roysamb E, Neale MC, et al. Dimensional representations of DSM-IV cluster B personality disorders in a population-based sample of Norwegian twins: a multivariate study. Psychol Med 2008; 38:1617-25; http://dx.doi.org/10.1017/S0033291708002924.
22. Soloff PH, Lynch KG, Kelly TM. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. J Pers Disord 2002; 16:201-14; http://dx.doi.org/10.1521/pedi.16.3.201.22542.
23. Famularo R, Kinscherff R, Fenton T. Posttraumatic stress disorder among children clinically diagnosed as borderline personality disorder. J Nerv Ment Dis 1991; 179:428-31; http://dx.doi.org/10.1097/00005053-199107000-00007.
24. Goldman SJ, D'Angelo EJ, DeMaso DR, Mezzacappa E. Physical and sexual abuse histories among children with borderline personality disorder. Am J Psychiatry 1992; 149:1723-6.
25. Herman JL, Perry JC, van der Kolk BA. Childhood trauma in borderline personality disorder. Am J Psychiatry 1989; 146:490-5.
26. Paris J, Zweig-Frank H, Guzder J. Risk factors for borderline personality in male outpatients. J Nerv Ment Dis 1994; 182:375-80; http://dx.doi.org/10.1097/00005053-199407000-00002.
27. Silk KR, Lee S, Hill EM, Lohr NE. Borderline personality disorder symptoms and severity of sexual abuse. Am J Psychiatry 1995; 152:1059-64.
28. G. Childhood sexual abuse and borderline personality disorder in the eating disorders. Child Abuse Negl 1994; 18:97-101; http://dx.doi.org/10.1016/0145-2134(94)90099-X.
29. Gunnar M, Quevedo K. The neurobiology of stress and development. Annu Rev Psychol 2007; 58:145-73; http://dx.doi.org/10.1146/annurev.psych.58.110405.085605.
30. Kaffman A, Meaney MJ. Neurodevelopmental sequelae of postnatal maternal care in rodents: clinical and research implications of molecular insights. J Child Psychol Psychiatry 2007; 48:224-44; http://dx.doi.org/10.1111/j.1469-7610.2007.01730.x.
31. McGowan PO, Suderman M, Sasaki A, Huang TC, Hallett M, Meaney MJ, et al. Broad epigenetic signature of maternal care in the brain of adult rats. PLoS ONE 2011; 6:14739; http://dx.doi.org/10.1371/journal.pone.0014739.
32. Ni X, Bismil R, Chan K, Sicard T, Bulgin N, McMain S, et al. Serotonin 2A receptor gene is associated with personality traits, but not to disorder, in patients with borderline personality disorder. Neurosci Lett 2006; 408:214-9; http://dx.doi.org/10.1016/j.neulet.2006.09.002.
33. Pascual J, Soler J, Baiget M, Cortes A, Menoyo A, Barrachina J, et al. Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Kuhlman Personality Questionnaire (ZKPQ). Actas Esp Psiquiatr 2007; 35:382-6.
34. Retz W, Retz-Junginger P, Supprian T, Thome J, Rosler M. Association of serotonin transporter promoter gene polymorphism with violence: relation with personality disorders, impulsivity and childhood ADHD psychopathology. Behav Sci Law 2004; 22:415-25; http://dx.doi.org/10.1002/bsl.589.
35. 3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord 2005; 37:57-60; http://dx.doi.org/10.1002/eat.20073.
36. Tadic A, Elsasser A, Victor A, von Cube R, Baskaya O, Wagner S, et al. Association analysis of serotonin receptor 1B (HTR1B) and brain-derived neurotrophic factorgene polymorphisms in Borderline personality disorder. J Neural Transm 2009; 116:1185-8. http://dx.doi.org/10.1007/s00702-009-0264-3.
37. Tadic A, Victor A, Baskaya O, von Cube R, Hoch J, Kouti I, et al. Interaction between gene variants of the serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) in borderline personality disorder. Am J Med Genet B Neuropsychiatr Genet 2009; 150:487-95; http://dx.doi.org/10.1002/ajmg.b.30843.
38. Grosjean B, Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci 2007; 32:103-15.
39. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297:851-4; http://dx.doi.org/10.1126/science.1072290.
40. Ni X, Sicard T, Bulgin N, Bismil R, Chan K, McMain S, et al. Monoamine oxidase a gene is associated with borderline personality disorder. Psychiatr Genet 2007; 17:153-7; http://dx.doi.org/10.1097/YPG.0b013e328016831c.
41. Müller DJ, Serretti A, Sicard T, Tharmalingam S, King N, Artioli P, et al. Further evidence of MAO-A gene variants associated with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144:37-40; http://dx.doi.org/10.1002/ajmg.b.30380.
42. Joyce PR, McHugh PC, McKenzie JM, Sullivan PF, Mulder RT, Luty SE, et al. A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients. Psychol Med 2006; 36:807-13; http://dx.doi.org/10.1017/S0033291706007288.
43. Zaboli G, Gizatullin R, Nilsonne A, Wilczek A, Jonsson EG, Ahnemark E, et al. Tryptophan hydroxylase-1 gene variants associate with a group of suicidal borderline women. Neuropsychopharmacology 2006; 31:1982-90; http://dx.doi.org/10.1038/sj.npp.1301046.
44. Tadic A, Elsasser A, Storm N, Baade U, Wagner S, Baskaya O, et al. Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder. World J Biol Psychiatry 2010; 11:45-58; http://dx.doi.org/10.3109/15622970903406226.
45. Joyce PR, McKenzie JM, Mulder RT, Luty SE, Sullivan PF, Miller AL, et al. Genetic, developmental and personality correlates of self-mutilation in depressed patients. Aust NZ J Psychiatry 2006; 40:225-9; http://dx.doi.org/10.1080/j.1440-614.2006.01778.x.
46. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005; 102:9341-6; http://dx.doi.org/10.1073/pnas.0503736102.
47. McGowan PO, Sasaki A, Huang TC, Unterberger A, Suderman M, Ernst C, et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE 2008; 3:2085; http://dx.doi.org/10.1371/journal.pone.0002085.
48. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004; 24:1478-85; http://dx.doi.org/10.1523/JNEUROSCI.4734-03.2004.
49. Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, et al. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry 2008; 64:645-52; http://dx.doi.org/10.1016/j.biopsych.2008.05.028.
50. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12:342-8; http://dx.doi.org/10.1038/nn.2270.
51. Cui H, Nishiguchi N, Yanagi M, Fukutake M, Mouri K, Kitamura N, et al. A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr Res 2010; 121:172-8; http://dx.doi.org/10.1016/j.schres.2010.05.003.
52. Silberberg G, Ben-Shachar D, Navon R. Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153:1318-28; http://dx.doi.org/10.1002/ajmg.b.31112.
53. Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V, et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res 2011; 129:183-90; http://dx.doi.org/10.1016/j.schres.2011.04.007.
54. Dammann RH, Kirsch S, Schagdarsurengin U, Dansranjavin T, Gradhand E, Schmitt WD, et al. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 2010; 36:171-9.
55. Murphy BC, O'Reilly RL, Singh SM. Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005; 133:37-42; http://dx.doi.org/10.1002/ajmg.b.30134.
56. Hendriks RW, Chen ZY, Hinds H, Schuurman RK, Craig IW. An X chromosome inactivation assay based on differential methylation of a CpG island coupled to a VNTR polymorphism at the 5' end of the monoamine oxidase A gene. Hum Mol Genet 1992; 1:187-94; http://dx.doi.org/10.1093/hmg/1.3.187.
57. Nordquist N, Oreland L. Monoallelic expression of MAOA in skin fibroblasts. Biochem Biophys Res Commun 2006; 348:763-7; http://dx.doi.org/10.1016/j.bbrc.2006.07.131.
58. Kaneda Y, Fujii A, Nagamine I. Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:983-92; http://dx.doi.org/10.1016/S0278-5846(01)00173-7.
59. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63:1209-16; http://dx.doi.org/10.1001/archpsyc.63.11.1209.
60. Coron B, Campion D, Thibaut F, Dollfus S, Preterre P, Langlois S, et al. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res 1996; 62:221-6; http://dx.doi.org/10.1016/0165-1781(96)02933-2.
61. Brunner HG. MAOA deficiency and abnormal behaviour: perspectives on an association. Ciba Found Symp 1996; 194:155-64.
62. Haavik J, Blau N, Thony B. Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 2008; 29:891-902; http://dx.doi.org/10.1002/humu.20700.
63. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
64. Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 2001; 20:7505-13; http://dx.doi.org/10.1038/sj.onc.1204940.
65. Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 2008; 88:161-70; http://dx.doi.org/10.1038/labinvest.3700707.
66. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 2006; 15:3132-45; http://dx.doi.org/10.1093/hmg/ddl253.
67. McGowan PO, Szyf M. Environmental epigenomics: understanding the effects of parental care on the epigenome. Essays Biochem 2010; 48:275-87; http://dx.doi.org/10.1042/bse0480275.
68. McGowan PO, Szyf M. The epigenetics of social adversity in early life: implications for mental health outcomes. Neurobiol Dis 2010; 39:66-72; http://dx.doi.org/10.1016/j.nbd.2009.12.026.
69. Yuferov V, Nielsen DA, Levran O, Randesi M, Hamon S, Ho A, et al. Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet Genomics 2011; 21:185-96.
70. Schilling E, Rehli M. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 2007; 90:314-23; http://dx.doi.org/10.1016/j.ygeno.2007.04.011.
71. Dansranjavin T, Krehl S, Mueller T, Mueller LP, Schmoll HJ, Dammann RH. The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. Cell Cycle 2009; 8:916-24; http://dx.doi.org/10.4161/cc.8.6.7934.
72. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2:2265-75; http://dx.doi.org/10.1038/nprot.2007.314.
73. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25:2532-4; http://dx.doi.org/10.1093/nar/25.12.2532.
74. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010; 9:264; http://dx.doi.org/10.1186/1476-4598-9-264.
75. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009; 4:571-6; http://dx.doi.org/10.4161/epi.4.8.10056.